NCT02004587View on ClinicalTrials.gov

Influence of Hepatic Impairment on Pharmacokinetic (PK) and Pharmacodynamic (PD) of Gemigliptin PK and PD After Multiple Oral Doses in Healthy White Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

May 31, 2014

Study Completion Date

July 31, 2014

Conditions

Hepatic Impairment

Interventions

DRUG

Gemigliptin

Gemigliptin is administered to each hepatic impairment subject for single oral dose. Also it is administered to healthy volunteer for single and multiple doses.

Trial Locations (1)

24105

CRS Clinical Research Services, Kiel